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Short Communication
Flash Glucose Monitoring (FGM) Can Contribute Better Glucose 
Variability and Treatment Satisfaction
Hiroshi Bando*
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Abstract
For adequate diagnosis and treatment for diabetes, there have been Self-Monitoring of Blood Glucose (SMBG), Continuous Glucose Monitoring 
(CGM) and Flash Glucose Monitoring (FGM).By applying FreeStyle Libre, many patients with diabetes mellitus have obtained better glucose 
variability. FGM can also contribute treatment satisfaction, which is evaluated by Diabetes Treatment Satisfaction Questionnaire (DTSQ) and 
Diabetes Therapy-Related Quality of Life (DTR-QOL) questionnaire. A report for patients with Type 2 Diabetes Mellitus (T2DM) showed that 
FGM continuation for 3 months contributed significant reduction of HbA1c and successive 3 months without FGM revealed stable HbA1c value, 
suggesting clinical psychological effect of FGM.
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Introduction
There has been the challenging situation of increasing obesity and 
aging population [1]. Consequently, the incidence of diabetes mellitus 
has been increasing worldwide [2,3]. Authors and collaborators have 
continued diabetic practice and research including continuous glucose 
monitoring (CGM) and Flash Glucose Monitoring (FGM) [4,5]. Several 
reports are observed concerning CGM, FGM and Self-Monitoring of 
Blood Glucose (SMBG), which indicate the development of diabetic 
research [6]. As FGM, FreeStyle Libre has been prevalent for some 
years. It has been applied for Type 1 diabetes mellitus (T1DM) and 
Type 2 diabetes mellitus (T2DM).
There was an observational study from regional diabetes database 
[7]. Subjects were 128 T1DM patients and HbA1c was checked 0,3,6,12 
months after using FGM system. On 6 months, FGM group showed 
significant decrease of HbA1c (8.0-7.6%, p=0.00), whereas SMBG 
group showed unchanged (7.9-7.9%, p=0.66). Thus, to change from 
SMBG to FGM contribute improvement of glucose variability for 
T1DM.
By applying FreeStyle Libre Flash Glucose Monitoring (FSL-FGM), 
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many diabetic patients have obtained better glucose variability. Then, 
what is the factors predicting HbA1c reduction? The research showed 
that 860 patients (average 46.7 years old) had baseline HbA1c 8.1%, in 
which 75% was type 1 DM [8]. Associated with FGM, HbA1c reduction 
more than 0.5% for 6 months was 22% of them. They showed median 
HbA1c reduction at 6 and 12 months was -0.82%. After multivariable 
regression analysis with several factors, SF-12 physical and mental 
component scores, baseline HbA1c was only significant different factor 
(p<0.001, R2 = 0.240). Thus, only high HbA1c at baseline would predict 
significant improvement of HbA1c during FGM application.
Clinical efficacy of FGM was found in comparison with FGM 
and SMBG in patients with type 2 diabetes mellitus (T2DM) [9]. The 
research was RCT study for 24 weeks with multi-center study from 5 
hospitals. The subjects were selected T2DM patients with 20-69 years 
old with HbA1c 7.5-8.4%. Subjects (n=100) were divided into two 
groups, which were FGM group and SMBG group. Both groups were 
educated to adjust their lifestyles to achieve pre-prandial blood glucose 
<130 mg/dL and postprandial blood glucose <180 mg/dL. Each group 
was provided with the intervention for 12 weeks. After that, without the 
intervention, the HbA1c status on 24 weeks were investigated. They did 
not receive FGM or SMBG from 13-24 weeks [9].
Main outcome included the changes in HbA1c at 24 weeks [9]. 
Second outcomes included BMI, BP, fasting plasma glucose, lipid 
profile and uric acid. Furthermore, diabetes treatment satisfaction 
questionnaire (DTSQ) was studied at 0 and 12 weeks. As a result, 
HbA1c changes at 12 weeks were -0.43% vs -0.30% in FGM (n=48) vs 
SMBG (n=45) group. However, HbA1c changes persisted at 24 weeks 
in only FGM group (-0.46%). The FGM group was 0.29% superior to 
SMBG group (p=0.014).
 When investigating in detail points, FGM group showed 
improvement and significant difference between the groups for mean 
glucose value, Time In Range (TIR) and Time Above Range (TAR) [9]. 
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Furthermore, FGM group showed the improvement of the Coefficient 
of Variation (CV), Mean Amplitude of Glycemic Excursions (MAGE) 
exceeding the standard deviation, and daily difference in blood glucose 
(MODD). These factors had significant differences between both 
groups. The result suggested that FGM suppressed mean blood glucose 
levels, diurnal blood glucose fluctuations, and daily disparities. As to 
the changes in DTSQ, only FGM group showed significant elevation 
from 26.5 to 29.9 points. On the other hand, SMBG group showed no 
changes. These results suggested that diabetic patients may improve 
and regulate their lifestyle inspired from the continuous glucose data 
of GFM. These beneficial changes were probably continued in the 
latter 12 weeks. The continuation of adequate diet habit seems to be 
rather difficult. For example, the Dietary Intervention Randomized 
Controlled Trial (DIRECT) showed the regain of the body weight in 
T2DM patients [10].
Formerly, SMBG was introduced to medical practice by the method 
of pricking the fingers. After that, FGM was evaluated for the beneficial 
effect of reducing frequency of hypoglycemia in RCT study [11]. FGM 
could also improve HbA1c values for T1DM in several investigations 
[12-14]. Furthermore, FGM was evaluated to be superior to SMBG in 
reducing the episode of hypoglycemia [15], and HbA1c value in T2DM 
patients with insulin treatment [16,17].
A recent report showed the efficacy of FGM. Subjects were 94 T2DM 
adult patients treated with basal-bolus insulin therapy [18]. After 
the application of FreeStyle Libre, they showed improved glycemic 
variability as follows: time period of glucose within normal range + 1.7 
hours/day, hyperglycemia period -1.6 hours/day, HbA1c -0.4% (each 
p<0.0001). Treatment satisfaction by DTSQ showed improved values 
increasing 11.8 points [19].
From the view point of satisfaction for FGM, a report was 
observed for patients with T1DM [20]. The protocol included 0,4,12 
weeks evaluation by two questionnaires. One is the DTSQ with eight 
questions such as satisfaction with current treatment, flexibility, 
convenience, understanding of diabetes, recommend treatment to 
others, willingness to continue [21,22]. Another is Diabetes Therapy-
Related Quality of Life (DTR-QOL) questionnaire with 29 items for 4 
groups, such as burden on social activities and daily activities, anxiety 
and dissatisfaction with treatment, hypoglycemia, and satisfaction with 
treatment [23]. The results showed the significant improvement of 
HbA1c (p=0.002) and the percentage of time within the target glucose 
range (p=0.016), burden in social activities (p=0.024) and treatment 
satisfaction (p=0.007). Thus, FGM contributed to glucose variability 
and patient satisfaction in T1D patients.
Conclusion
FGM has been known for its usefulness of prompt grasping the 
current blood glucose level. A new report shows the characteristic point 
that the experience of FGM can contribute the better glucose variability 
after discontinuation of FGM for months. The main cause seems to be 
due to understanding the relationship between detail fluctuation of 
glucose and daily life style in each subject. Furthermore, GGM may 
give each patient treatment satisfaction, which can make the patient 
continue better diabetic control with adequate lifestyle for long.
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